• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sanofi-Aventis

Kaleo plans 2017 U.S. relaunch for EpiPen competitor Auvi-Q

October 26, 2016 By Sarah Faulkner

Kaleo

Kaléo Inc. said today that it plans to relaunch its Auvi-Q injector for emergency allergy treatment in the U.S. during the 1st half of 2017, according to Reuters.  The Richmond, Va.-based company’s device was recalled last year after concerns about the accuracy of delivered dose. Sanofi (NYSE:SNY) made and licensed the Auvi-Q device from Kaléo, but returned rights to […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured Tagged With: Kaleo Inc, Mylan, Sanofi-Aventis

Sanofi sues Merck over injected insulin

September 19, 2016 By Sarah Faulkner

Sanofi, Merck

Sanofi Aventis (NYSE:SNY) said today that it filed a patent infringement lawsuit against Merck Sharp & Dohme Corp. (NYSE:MRK) over 10 U.S. patents related to its injected insulin device. The Paris-based company said it is seeking an injunction and damages from Merck for filing a new drug application with the FDA that challenged 10 of Sanofi’s patents […]

Filed Under: Diabetes, Drug-Device Combinations, Legal News Tagged With: Merck, Sanofi-Aventis

Sanofi, Google’s Verily launch $500m Onduo diabetes JV

September 12, 2016 By Brad Perriello

Sanofi, Verily form Onduo

Sanofi (NYSE:SNY) and Verily Life Sciences, the healthcare play owned by Google parent Alphabet (NSDQ:GOOGL), are launching a joint venture to tackle diabetes. The Cambridge, Mass.-based Onduo JV will aim to combine Verily’s expertise in miniaturized electronics, analytics, and consumer software with Sanofi’s diabetes program. Dr. Joshua Riff, formerly senior vice president of prevention & wellbeing at UnitedHealth‘s (NYSE:UNH) Optum business, was tapped to be […]

Filed Under: Diabetes, Drug-Device Combinations, Wall Street Beat Tagged With: Onduo, Sanofi-Aventis, Verily

FDA request delays timeline for Sanofi’s iGlarLixi drug-device combo for diabetes

August 24, 2016 By drugdelivery

By Sarah Faulkner The FDA’s request for more data on the iGlarLixi drug-device combination for treating Type II diabetes pushed the timeline for a decision back 3 months, Sanofi (NYSE:SNY) and Zealand Pharma (CPH:ZEAL) said last week. Sanofi said August 19 that it submitted a new data package for iGlarLixi, an injection pen designed to […]

Filed Under: Diabetes, Drug-Device Combinations, Food & Drug Administration (FDA) Tagged With: Sanofi-Aventis, Zealand Pharma

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 6
  • Page 7
  • Page 8

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS